menu
    • menu

    List of Drug Master Files (KDMF) of Active Pharmaceutical Ingredients (APIs) submitted by Pfizer Inc to the Review Authority in Korea.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across...
    At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative bioph

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Pfizer IncUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    235 East 42nd Street New York, NY 10017
    Telephone
    Telephone
    +1 212-733-2323
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.pfizer.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/pfizer/
    Twitter
    Twitter
    https://twitter.com/Pfizer

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPhI Worldwide, Milan

    CPhI Worldwide, Milan

    Not Confirmed

    envelop Contact Supplier

    CPhI Worldwide, Milan

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “We’re unlocking life-changing potential in complex molecules, without sacrificing time to market”

    “We’re unlocking life-changing potential in complex molecules, without sacrificing time to market”

    This week, SpeakPharma interviews Mike Riley, CEO of Veranova, a leading contract development and manufacturing organization (CDMO) confidently mastering complex APIs as it marks its second year as an independent company. Riley discusses Veranova’s key achievements, including a US$ 30 million investment in their Devens, Massachusetts (US) site to expand capabilities in antibody-drug conjugates (ADCs) and highly potent APIs (HPAPIs), and how it is navigating the increasing complexity of molecules. 🔑 HIGHLIGHTS// Veranova’s key achievements / navigating the increasing complexity of molecules Veranova is celebrating its second year as a stand-alone company. Can you share Veranova’s key milestones and achievements in its first two years? We have achieved incredible milestones over the last two years, thanks to the dedication and hard work of our team. Our first 12 months focused on establishing ourselves as an independent CDMO by building on the 50 years of expertise that we brought with us. In addition, we expanded our capabilities and applied a more agile approach available to us as a company singularly focused on life sciences. This has allowed us to move into our second year with clear and strategic goals for generating growth in our sites, people, capabilities, and offerings. Since being appointed as CEO in May 2023, I’ve had the pleasure of witnessing some exciting growth milestones of my own. Most recently, we announced an estimated US$ 30 million investment in our Devens, Massachusetts, site. This expansion will allow us to build upon existing development and manufacturing capabilities in ADCs and HPAPIs that will address the growing demand for strong US-based capacity in these key drug modalities. We also appointed our Advisory Board, thereby bolstering Veranova’s in-house expertise. Made up of four distinguished leaders in pharma and biopharma – including Dr. Carolyn Bertozzi, the 2022 Nobel Laureate in Chemistry – the Board has provided thought-leadership, guidance and expertise as we develop and execute our strategic growth and ideas. We were also proud to be recognized as one of the Society of Chemical Manufacturers and Affiliates’ 12 companies for industry-leading safety programs in 2023 and as a part of the Medicine Maker’s Power List in 2024. 🔑 HIGHLIGHTS// US$ 30 million investment in our Devens, Massachusetts, site / appointed our Advisory Board Molecules are becoming increasingly complex. Can you elaborate on how Veranova’s current capabilities are strategically designed to address this trend in the coming years? The pharmaceutical pipeline is witnessing an increasing number of complex and highly potent molecules. This trend is driven by the demand for more targeted, patient-centric therapeutics and the focus on innovative modalities such as ADCs and other bioconjugates. At Veranova, our expertise, world-class facilities, and scientific excellence enable us to provide our customers with the clarity and solutions needed to manage this development and manufacturing complexity and ultimately deliver the required treatments to customers and patients. Our people are key to this approach. We have an expert team ready to collaborate with customers at any point, from early development through large-scale commercial production. Our services include world-leading crystallization development, process development, and specialized manufacturing expertise for complex synthetic molecules, including those requiring chromatography capabilities. In many cases, we can provide all these under one roof. Our service offering to our customers is also based on the foundational element of strong quality and compliance systems. We operate multiple facilities approved by the US FDA, UK’s MHRA and other regulatory authorities and are continually focused on ways to strengthen our global quality management system. Looking ahead, we are focused on continually investing in our facilities and team to meet growing complexity, as evidenced by our recent announcement of new investment in our Devens site. This investment signals our commitment to providing state-of-the-art capacity and capabilities to enable these next-generation therapies to reach patients. It is a key milestone as we advance Veranova’s broader growth strategy. 🔑 HIGHLIGHTS// provide our customers with clarity and solutions / world-leading crystallization development / expertise for complex synthetic molecules / strong quality and compliance systems How is Veranova approaching the challenge of designing and manufacturing effective linker molecules for ADCs? As a leader in complex linker-payload synthesis, Veranova is committed to unlocking the life-changing potential of ADCs without letting their complexities slow down the development of much-needed cancer therapies. ADCs are intricate, multi-component molecules that require extensive expertise and agile collaboration to overcome unique development challenges. With over a decade of experience in ADC linker-payload systems, we have developed the ability to anticipate challenges and avoid common pitfalls. The ADC linker-payload components are complex structures that are difficult to crystallize and require specialized high-potent handling. Veranova’s differentiated combination of world-leading crystallization development capabilities, complex synthesis experience, chromatography expertise and high-potent-handling experience put us in a unique position to solve these challenges for customers and speed their products to the clinic. We prioritize getting it right the first time, minimizing change orders and ensuring high-quality results. We have developed a robust phase-appropriate strategy that is backed by state-of-the-art analytical equipment and regulatory procedures to ensure our partners can rapidly progress their ADC projects from pre-clinical to commercialization. 🔑 HIGHLIGHTS// unlocking the life-changing potential of ADCs / ensuring our partners can rapidly progress their ADC projects Can you specify how Veranova is using artificial intelligence (AI) to optimize manufacturing processes that can reduce costs and environmental footprint as well as speed up development? In May 2024, Veranova announced a partnership with Phorum.AI to leverage AI to optimize pharmaceutical manufacturing processes. This collaboration aims to enable the rapid development of processes that can drive efficiency and reduce costs while maximizing environmental sustainability. Our goal is to combine Veranova’s extensive empirical manufacturing dataset of owned APIs and drug master files with Phorum.AI’s computational chemistry engine in order to create a more powerful process-development tool for the benefit of Veranova’s and Phorum’s customers. At Veranova, we are constantly looking to employ innovative technologies and approaches to improve efficiency, accelerate time to market and reduce environmental footprint. We have the means to work with a variety of partners who have unique project requirements, without sacrificing time to market.  🔑 HIGHLIGHTS// partnership with Phorum.AI / create a more powerful process-development tool / improve efficiency, accelerate time to market and reduce environmental footprint

    Impressions: 1852

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/we-re-unlocking-life-changing-potential-in-complex-molecules-without-sacrificing-time-to-market

    #SpeakPharma With Veranova
    10 Sep 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    BMS, Bayer, Takeda, Pfizer downsize to combat cost pressures, meet restructuring plans

    BMS, Bayer, Takeda, Pfizer downsize to combat cost pressures, meet restructuring plans

    Over the last two years, there has been a significant surge in layoffs by pharmaceutical and biotech companies. The trend spilled over to 2024. Data compiled by PharmaCompass indicates that between January and early-September, around 150 companies had implemented layoffs. Bristol Myers Squibb (BMS) tops the list of companies that downsized, with a staggering 2,284 job cuts. Bayer stood second at 1,816 retrenchments, followed by Takeda Pharmaceuticals at 1,155. Johnson & Johnson’s spin-off Kenvue is slashing over 1,000 jobs this year, while Roche subsidiary Genentech is cutting 529 positions, and Novartis is going ahead with its multi-year restructuring, and cutting another 770 jobs. One of the primary drivers of layoffs has been the need for companies to streamline operations and reduce costs. Many firms have faced financial pressures due to reasons such as declining revenues, increased competition, and the high costs associated with drug development. The current wave of layoffs has encompassed geographies – from traditional pharma strongholds like New Jersey, biotech hubs in Massachusetts and California, to Europe (particularly Germany and Switzerland). This is not to suggest that job cuts are a norm. Certain segments have been experiencing substantial growth and job creation. This includes companies like Eli Lilly and Novo Nordisk that have experienced remarkable growth due to the efficacy of their glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs that treats type 2 diabetes and obesity.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 as of Sept. 7 (Free Excel Available) BMS cuts 2,284 jobs to meet cost targets, Bayer hands pink slips to 1,816 employees Several large drugmakers have announced job cuts this year in order to meet their cost cutting goals, or as part of their restructuring exercise. BMS’ revenue had declined from US$ 46.2 billion in 2022 to US$ 45 billion in 2023. The financial pressure has compelled it to cut 2,284 jobs so far in this year, a move that sent shockwaves through the industry. Overall, BMS hopes to save approximately US$ 1.5 billion in costs by 2025 through this “strategic productivity initiative”. In Europe, Swiss-based companies like Novartis and Roche have announced substantial job cuts, while Bayer is reducing its workforce globally.  Bayer is laying off 1,816 employees worldwide, including 150 in Basel, Switzerland. A majority of these are management roles as the German drugmaker seeks to target € 500 million (US$ 557 million) in cost savings in 2024 and € 2 billion (US$ 2.23 billion) in 2026. Japanese drugmaker Takeda plans to eliminate 1,155 positions, including 324 jobs in San Diego and 641 in Massachusetts. Takeda is also winding down production and R&D operations in Austria, resulting in 190 job losses. Starting next month, Genentech, a Roche subsidiary, will lay off 93 employees in San Francisco. Earlier this year, Genentech trimmed roughly 3 percent of its workforce across several departments, impacting 436 employees. Roche also laid off around 340 employees in its product development team. Novartis has been undergoing a significant restructuring exercise since 2022, when it announced 8,000 job cuts in its global workforce. This year, it announced an additional 770 job cuts in its product development organization, separate from the previous reductions. Once again, it was workforces in Switzerland (440 job cuts) and US (269 job cuts) that bore the brunt. Tylenol and Band-Aid maker Kenvue, which spun off from J&J last year, announced plans to cut 920 jobs, representing about 4 percent of its global workforce. Additionally, the company will lay off 51 employees in New Jersey and 84 in California. These layoffs are part of Kenvue’s efforts to adjust its cost structure and become more competitive.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 as of Sept. 7 (Free Excel Available)  Perrigo, Emergent Bio, Catalent, BioMarin trim workforces amid strategic shifts Several mid-size companies too are under tremendous cost pressures, with some of them feeling the need to reinvent themselves for the future. In February this year, Perrigo had embarked on ‘Project Energize’, a three-year initiative aimed at boosting organizational agility and achieving long-term success. As part of this project, Perrigo is cutting costs and laying off 6 percent of its staff, which translates into nearly 550 employees. CDMO-turned-biopharma Emergent BioSolutions plans to reduce its workforce by about 300 employees. The Maryland-based multinational is closing its Baltimore-Bayview drug substance manufacturing facility and its Rockville drug product facility in the state. Rare disease biotech BioMarin laid off 395 employees globally, about 12 percent of its workforce, as part of “organizational redesign efforts” to prioritize its new strategy with its hemophilia A gene therapy Roctavian and to preserve cash. Drug-delivery specialist Catalent has also been significantly impacted by restructuring efforts ever since it announced 1,100 layoffs in December. It had then attributed its fall in revenue to declining Covid-related sales, but had also noted that future GLP-1 manufacturing revenues could help stabilize its finances. True enough — it subsequently announced that it is in the process of being acquired by Novo Nordisk’s parent company for US$ 16.5 billion. However, Catalent reported reducing its headcount by an additional 300 in the fourth quarter of 2023.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 as of Sept. 7 (Free Excel Available)  Pfizer job cuts continue to trickle in; Lykos, Lyra downsize after pipeline setbacks Clinical trial failures and financial constraints have also played a significant role in this year’s wave of layoffs. At Pfizer, job cuts continued to trickle in, with some estimates putting the number at 1,500 employees in 2024. These include 285 at its vaccine R&D site in New York, and 52 in San Francisco. The Comirnaty maker also pulled the plug on a long-anticipated, near-complete Seagen drug manufacturing plant in Everett, Washington. About 120 employees at the site were let go.  It has been a tumultuous time for Lykos Therapeutics, following the US Food and Drug Administration’s rejection of its MDMA-assisted therapy for post-traumatic stress disorder. Lykos announced laying off 75 percent of its staff (i.e. 75 employees). Its founder, who had spent 38 years working on the therapy, left the company and so did its CEO. However, Lykos has not given up and has roped in a Janssen veteran as senior medical advisor to get the therapy past the finish line. Similarly, Lyra Therapeutics is laying off 75 percent of its workforce (i.e. 87 employees) following disappointing late-stage results for its implant to treat chronic rhino-sinusitis. The retrenchments include its chief technology officer.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 as of Sept. 7 (Free Excel Available)  Our view Technology, regulatory and pricing pressures are shaping strategies of pharmaceutical companies. The drive to do more with less could accelerate the adoption of artificial intelligence, machine learning, and automation in drug discovery and development processes. The employment landscape is certainly evolving. We foresee significant changes in the skills required for pharmaceutical and biotech careers, with a growing emphasis on data science and computational biology.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 560

    https://www.pharmacompass.com/radio-compass-blog/bms-bayer-takeda-pfizer-downsize-to-combat-cost-pressures-meet-restructuring-plans

    #PharmaFlow by PHARMACOMPASS
    19 Sep 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer sets up analytics capability centre in Mumbai
    Pfizer sets up analytics capability centre in Mumbai

    18 Sep 2024

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pfizer-sets-up-analytics-capability-centre-in-mumbai/articleshow/113464623.cms

    ECONOMICTIMES
    18 Sep 2024
    Share Share
    Pfizer To Webcast October 29 Conference Call With Analysts To The Public
    Pfizer To Webcast October 29 Conference Call With Analysts To The Public

    17 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240917734330/en

    BUSINESSWIRE
    17 Sep 2024
    Share Share
    ESMO: Pfizer drug helps cancer patients gain weight
    ESMO: Pfizer drug helps cancer patients gain weight

    17 Sep 2024

    // #N/A

    https://pharmaphorum.com/news/esmo-pfizer-drug-helps-cancer-patients-gain-weight

    #N/A
    17 Sep 2024
    Share Share
    Pfizer Presents Phase 2 Data On Ponsegromab For Cancer Cachexia
    Pfizer Presents Phase 2 Data On Ponsegromab For Cancer Cachexia

    16 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240913347614/en

    BUSINESSWIRE
    16 Sep 2024
    Share Share
    Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
    Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

    14 Sep 2024

    // Michael Erman REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-pushing-braf-lung-cancer-mutation-testing-grow-market-braftovi-2024-09-14/

    Michael Erman REUTERS
    14 Sep 2024
    Share Share
    Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Response In NSCLC
    Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Response In NSCLC

    14 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240913128678/en

    BUSINESSWIRE
    14 Sep 2024
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck Receives Positive EU CHMP Opinion for KEYTRUDA® Plus Padcev® in Urothelial Carcinoma

    Details:

    Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) is approved by USFDA for the first-line treatment of adult patients with locally advanced or metastatic urothelial cancer.


    Lead Product(s): Pembrolizumab,Enfortumab Vedotin

    Therapeutic Area: Oncology Brand Name: Keytruda

    Study Phase: ApprovedProduct Type: Large molecule

    Recipient: Merck & Co

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 26, 2024

    blank

    01

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pembrolizumab,Enfortumab Vedotin

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Recipient : Merck & Co

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Merck Receives Positive EU CHMP Opinion for KEYTRUDA® Plus Padcev® in Urothelial Carcinoma

    Details : Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) is approved by USFDA for the first-line treatment of adult patients with locally advanced or metastatic urothelial cancer.

    Brand Name : Keytruda

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    July 26, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    European Commission Approves Pfizer’s DURVEQTIX® Gene Therapy for Hemophilia B

    Details:

    Durveqtix (fidanacogene elaparvovec) is an adeno-associated viral (AAV) vector-based gene therapy approved for the treatment of adults with moderately severe to severe hemophilia B.


    Lead Product(s): Fidanacogene elaparvovec

    Therapeutic Area: Genetic Disease Brand Name: Durveqtix

    Study Phase: ApprovedProduct Type: Cell and Gene therapy

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 25, 2024

    blank

    02

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fidanacogene elaparvovec

    Therapeutic Area : Genetic Disease

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    European Commission Approves Pfizer’s DURVEQTIX® Gene Therapy for Hemophilia B

    Details : Durveqtix (fidanacogene elaparvovec) is an adeno-associated viral (AAV) vector-based gene therapy approved for the treatment of adults with moderately severe to severe hemophilia B.

    Brand Name : Durveqtix

    Molecule Type : Cell and Gene therapy

    Upfront Cash : Not Applicable

    July 25, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pfizer Announces Topline Results from Phase 3 Hemophilia A Gene Therapy Trial

    Details:

    PF-07055480 (giroctocogene fitelparvovec) a novel, investigational gene therapy containing modified B-domain deleted human coagulation FVIII gene. It is being investigated for treating hemophilia A.


    Lead Product(s): Giroctocogene Fitelparovec

    Therapeutic Area: Genetic Disease Brand Name: PF-07055480

    Study Phase: Phase IIIProduct Type: Cell and Gene therapy

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 24, 2024

    blank

    03

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Giroctocogene Fitelparovec

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Pfizer Announces Topline Results from Phase 3 Hemophilia A Gene Therapy Trial

    Details : PF-07055480 (giroctocogene fitelparvovec) a novel, investigational gene therapy containing modified B-domain deleted human coagulation FVIII gene. It is being investigated for treating hemophilia A.

    Brand Name : PF-07055480

    Molecule Type : Cell and Gene therapy

    Upfront Cash : Not Applicable

    July 24, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    VALOR Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

    Details:

    VLA15, an alum-adjuvanted formulation administered intramuscularly, is a vaccine candidate currently undergoing clinical development for the treatment of Lyme disease.


    Lead Product(s): VLA15

    Therapeutic Area: Infections and Infectious Diseases Brand Name: VLA15

    Study Phase: Phase IIIProduct Type: Vaccine

    Recipient: Valneva

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 17, 2024

    blank

    04

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : VLA15

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Recipient : Valneva

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    VALOR Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

    Details : VLA15, an alum-adjuvanted formulation administered intramuscularly, is a vaccine candidate currently undergoing clinical development for the treatment of Lyme disease.

    Brand Name : VLA15

    Molecule Type : Vaccine

    Upfront Cash : Not Applicable

    July 17, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pfizer Advances Once-Daily Oral GLP-1 Agonist Danuglipron Development

    Details:

    PF-06882961 (danuglipron) is an oral GLP-1R agonist smalll molecule candidate, which is being evaluated for the treatment of adults with obesity and without type 2 diabetes.


    Lead Product(s): Danuglipron

    Therapeutic Area: Nutrition and Weight Loss Brand Name: PF-06882961

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 11, 2024

    blank

    05

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Danuglipron

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Pfizer Advances Once-Daily Oral GLP-1 Agonist Danuglipron Development

    Details : PF-06882961 (danuglipron) is an oral GLP-1R agonist smalll molecule candidate, which is being evaluated for the treatment of adults with obesity and without type 2 diabetes.

    Brand Name : PF-06882961

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    July 11, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Evotec and Pfizer Collaborate to Advance Drug Discovery in France

    Details:

    Evotec will collaborate with Pfizer to discover, and research potential new first-in-class therapeutic approaches for the treatment of metabolic and infectious diseases.


    Lead Product(s): Undisclosed

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: DiscoveryProduct Type: Undisclosed

    Recipient: Evotec

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration July 10, 2024

    blank

    06

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Genetic Disease

    Highest Development Status : Discovery

    Recipient : Evotec

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Evotec and Pfizer Collaborate to Advance Drug Discovery in France

    Details : Evotec will collaborate with Pfizer to discover, and research potential new first-in-class therapeutic approaches for the treatment of metabolic and infectious diseases.

    Brand Name : Undisclosed

    Molecule Type : Undisclosed

    Upfront Cash : Undisclosed

    July 10, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pfizer and BioNTech Get Positive CHMP Opinion for Omicron COVID-19 Vaccine

    Details:

    Comirnaty JN.1 (Omi JN.1), a COVID-19 mRNA vaccine has achieved positive CHMP opinion by EMA for Omicron JN.1 lineage of SARS-CoV-2 infection in individuals 6 months of age and older.


    Lead Product(s): BNT162b2

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Comirnaty JN.1

    Study Phase: Phase IIIProduct Type: Vaccine

    Recipient: BioNTech

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 27, 2024

    blank

    07

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BNT162b2

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Recipient : BioNTech

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Pfizer and BioNTech Get Positive CHMP Opinion for Omicron COVID-19 Vaccine

    Details : Comirnaty JN.1 (Omi JN.1), a COVID-19 mRNA vaccine has achieved positive CHMP opinion by EMA for Omicron JN.1 lineage of SARS-CoV-2 infection in individuals 6 months of age and older.

    Brand Name : Comirnaty JN.1

    Molecule Type : Vaccine

    Upfront Cash : Not Applicable

    June 27, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pfizer's Elrexfio Shows Positive Results in Phase 2 RRMM Study

    Details:

    Elrexfio (elranatamab) is an off-the-shelf, BCMA-CD3-directed bispecific antibody immunotherapy. It is being evaluated for the treatment of relapsed and refractory multiple myeloma.


    Lead Product(s): Elranatamab

    Therapeutic Area: Oncology Brand Name: Elrexfio

    Study Phase: Phase IIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 15, 2024

    blank

    08

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Elranatamab

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Pfizer's Elrexfio Shows Positive Results in Phase 2 RRMM Study

    Details : Elrexfio (elranatamab) is an off-the-shelf, BCMA-CD3-directed bispecific antibody immunotherapy. It is being evaluated for the treatment of relapsed and refractory multiple myeloma.

    Brand Name : Elrexfio

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    June 15, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Relay Therapeutics, Pfizer to Collaborate on Atirmociclib and RLY-2608 Clinical Trial

    Details:

    The collaboration with Pfizer to evaluate atirmociclib, selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.


    Lead Product(s): RLY-2608,Atirmociclib,Fulvestrant

    Therapeutic Area: Oncology Brand Name: RLY-2608

    Study Phase: PreclinicalProduct Type: Small molecule

    Recipient: Relay Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration June 05, 2024

    blank

    09

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RLY-2608,Atirmociclib,Fulvestrant

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Recipient : Relay Therapeutics

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Relay Therapeutics, Pfizer to Collaborate on Atirmociclib and RLY-2608 Clinical Trial

    Details : The collaboration with Pfizer to evaluate atirmociclib, selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.

    Brand Name : RLY-2608

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    June 05, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Tisotumab Vedotin Phase 2 Shows Antitumor Activity in Recurrent Head and Neck Cancer

    Details:

    Tivdak (tisotumab vedotin) is an ADC that acts as coagulation factor III binding agent & tubulin inhibitor. It is being evaluated for the treatment of Head and Neck Squamous Cell Carcinoma.


    Lead Product(s): Tisotumab Vedotin,Pembrolizumab,Carboplatin

    Therapeutic Area: Oncology Brand Name: Tivdak

    Study Phase: Phase IIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 03, 2024

    blank

    10

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed

    Pfizer Inc

    U.S.A
    arrow
    BioProcess International
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tisotumab Vedotin,Pembrolizumab,Carboplatin

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Tisotumab Vedotin Phase 2 Shows Antitumor Activity in Recurrent Head and Neck Cancer

    Details : Tivdak (tisotumab vedotin) is an ADC that acts as coagulation factor III binding agent & tubulin inhibitor. It is being evaluated for the treatment of Head and Neck Squamous Cell Carcinoma.

    Brand Name : Tivdak

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    June 03, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Pfizer Inc and get a quotation

    Pfizer Inc is a supplier offers 213 products (APIs, Excipients or Intermediates).

    Find a price of Betamethyl Epoxide bulk with DMF, JDMF offered by Pfizer Inc

    Find a price of Epoprostenol Sodium bulk with DMF, JDMF offered by Pfizer Inc

    Find a price of Methylprednisolone bulk with DMF, CEP offered by Pfizer Inc

    Find a price of Prednisolone bulk with JDMF offered by Pfizer Inc

    Find a price of Atorvastatin bulk with JDMF offered by Pfizer Inc

    Find a price of Dexamethasone bulk with JDMF offered by Pfizer Inc

    Find a price of Estradiol Cypionate bulk with DMF offered by Pfizer Inc

    Find a price of Estramustine Phosphate Sodium bulk with DMF offered by Pfizer Inc

    Find a price of Methylprednisolone Acetate bulk with DMF offered by Pfizer Inc

    Find a price of Alprazolam bulk with CEP offered by Pfizer Inc

    Find a price of Betamethasone bulk offered by Pfizer Inc

    Find a price of Betamethasone Valerate bulk offered by Pfizer Inc

    Find a price of Cabergoline bulk offered by Pfizer Inc

    Find a price of Calicheamicin bulk with DMF offered by Pfizer Inc

    Find a price of CAS 50-28-2 bulk offered by Pfizer Inc

    Find a price of Celecoxib bulk with JDMF offered by Pfizer Inc

    Find a price of Chlormadinone Acetate bulk with JDMF offered by Pfizer Inc

    Find a price of Clindamycin Palmitate bulk with DMF offered by Pfizer Inc

    Find a price of Clindamycin Phosphate bulk with DMF offered by Pfizer Inc

    Find a price of Cortisone bulk offered by Pfizer Inc

    Find a price of Diflorasone bulk offered by Pfizer Inc

    Find a price of Dinoprostone bulk with DMF offered by Pfizer Inc

    Find a price of Doxorubicin Hydrochloride bulk with DMF offered by Pfizer Inc

    Find a price of Flumethasone bulk offered by Pfizer Inc

    Find a price of Fluoxymesterone bulk offered by Pfizer Inc

    Find a price of Glipizide bulk with DMF offered by Pfizer Inc

    Find a price of Hydrocortisone Sodium Succinate bulk with CEP offered by Pfizer Inc

    Find a price of Lincomycin Hydrochloride bulk with DMF offered by Pfizer Inc

    Find a price of Megestrol Acetate bulk with DMF offered by Pfizer Inc

    Find a price of Methylprednisolone bulk offered by Pfizer Inc

    Find a price of Methylprednisolone Hemisuccinate bulk with CEP offered by Pfizer Inc

    Find a price of Piperacillin Sodium bulk offered by Pfizer Inc

    Find a price of Piroxicam bulk with CEP offered by Pfizer Inc

    Find a price of Prednisolone Acetate bulk offered by Pfizer Inc

    Find a price of Progesterone bulk with JDMF offered by Pfizer Inc

    Find a price of Triamcinolone bulk offered by Pfizer Inc

    Find a price of Triamcinolone Acetonide bulk offered by Pfizer Inc

    Find a price of Triamcinolone Diacetate bulk offered by Pfizer Inc

    Find a price of 9-Aminocamptothecin bulk offered by Pfizer Inc

    Find a price of Acecainide bulk offered by Pfizer Inc

    Find a price of Acivicin bulk offered by Pfizer Inc

    Find a price of Amphotericin B bulk offered by Pfizer Inc

    Find a price of Ampicillin Sodium bulk offered by Pfizer Inc

    Find a price of Ampicillin Trihydrate bulk offered by Pfizer Inc

    Find a price of Arginine Vasopressin bulk offered by Pfizer Inc

    Find a price of Arlitene bulk offered by Pfizer Inc

    Find a price of Aspirin bulk offered by Pfizer Inc

    Find a price of Bacampicillin bulk offered by Pfizer Inc

    Find a price of Bacitracin Zinc bulk offered by Pfizer Inc

    Find a price of Benzylpenicillin Sodium bulk offered by Pfizer Inc

    Find a price of Betamethasone Benzoate bulk offered by Pfizer Inc

    Find a price of Betamethasone Dipropionate bulk offered by Pfizer Inc

    Find a price of Carbenicillin Indanyl bulk offered by Pfizer Inc

    Find a price of Carboxylic Acid bulk offered by Pfizer Inc

    Find a price of CAS 71-58-9 bulk offered by Pfizer Inc

    Find a price of Cefixime bulk offered by Pfizer Inc

    Find a price of Cefoperazone Sodium bulk offered by Pfizer Inc

    Find a price of Chloramphenicol Palmitate bulk offered by Pfizer Inc

    Find a price of Chloramphenicol Succinate Acid bulk offered by Pfizer Inc

    Find a price of Chlorhexidine Gluconate bulk offered by Pfizer Inc

    Find a price of Chlorpropamide bulk offered by Pfizer Inc

    Find a price of Chlortetracycline Hydrochloride bulk offered by Pfizer Inc

    Find a price of Chondroitin Sulfate Sodium bulk offered by Pfizer Inc

    Find a price of Clindamycin Hydrochloride bulk offered by Pfizer Inc

    Find a price of Clindamycin Phosphate bulk offered by Pfizer Inc

    Find a price of Cycloheximide bulk offered by Pfizer Inc

    Find a price of Cytarabine bulk offered by Pfizer Inc

    Find a price of Dacarbazine bulk offered by Pfizer Inc

    Find a price of Deferoxamine Mesylate bulk offered by Pfizer Inc

    Find a price of Demeclocycline Hydrochloride bulk offered by Pfizer Inc

    Find a price of Diphenhydramine bulk offered by Pfizer Inc

    Find a price of Doxorubicin Hydrochloride bulk offered by Pfizer Inc

    Find a price of Doxycycline Hyclate bulk offered by Pfizer Inc

    Find a price of Edoxudin bulk offered by Pfizer Inc

    Find a price of Erythromycin bulk offered by Pfizer Inc

    Find a price of Erythromycin Stearate bulk offered by Pfizer Inc

    Find a price of Estradiol bulk offered by Pfizer Inc

    Find a price of Estramustine bulk offered by Pfizer Inc

    Find a price of Ethinyl Estradiol bulk offered by Pfizer Inc

    Find a price of Etodolac bulk offered by Pfizer Inc

    Find a price of Exemestane bulk offered by Pfizer Inc

    Find a price of Fedotozine Tartrate bulk offered by Pfizer Inc

    Find a price of Fludrocortisone Acetate bulk offered by Pfizer Inc

    Find a price of Fluocinolone Acetonide bulk offered by Pfizer Inc

    Find a price of Fluorometholone bulk offered by Pfizer Inc

    Find a price of Hydrocortisone bulk offered by Pfizer Inc

    Find a price of Hydrocortisone Sodium Succinate bulk offered by Pfizer Inc

    Find a price of Hydrogen Peroxide bulk offered by Pfizer Inc

    Find a price of Hydroxyprogesterone Caproate bulk offered by Pfizer Inc

    Find a price of Ibuprofen bulk offered by Pfizer Inc

    Find a price of Idarubicin Hydrochloride bulk offered by Pfizer Inc

    Find a price of Lysergic Acid bulk offered by Pfizer Inc

    Find a price of Lysine Hydrochloride bulk offered by Pfizer Inc

    Find a price of Meclofenamic Acid bulk offered by Pfizer Inc

    Find a price of Medroxyprogesterone Acetate bulk offered by Pfizer Inc

    Find a price of Medrysone bulk offered by Pfizer Inc

    Find a price of Menogarol bulk offered by Pfizer Inc

    Find a price of Metergoline bulk offered by Pfizer Inc

    Find a price of Methacycline Hydrochloride bulk offered by Pfizer Inc

    Find a price of Methaqualone bulk offered by Pfizer Inc

    Find a price of Methotrexate bulk offered by Pfizer Inc

    Find a price of Methyl Testosterone bulk offered by Pfizer Inc

    Find a price of Methylprednisolone Hemisuccinate bulk offered by Pfizer Inc

    Find a price of Minocycline Hydrochloride bulk offered by Pfizer Inc

    Find a price of Minoxidil bulk offered by Pfizer Inc

    Find a price of Mithramycin bulk offered by Pfizer Inc

    Find a price of Neomycin Sulfate bulk offered by Pfizer Inc

    Find a price of Nicotine bulk offered by Pfizer Inc

    Find a price of Nystatin bulk offered by Pfizer Inc

    Find a price of Olsalazine bulk offered by Pfizer Inc

    Find a price of Oxytetracycline Calcium bulk offered by Pfizer Inc

    Find a price of Oxytetracycline Dihydrate bulk offered by Pfizer Inc

    Find a price of Oxytetracycline Hydrochloride bulk offered by Pfizer Inc

    Find a price of Penicillin G Benzathine bulk offered by Pfizer Inc

    Find a price of Penicillin G Procaine bulk offered by Pfizer Inc

    Find a price of Penicillin V Potassium bulk offered by Pfizer Inc

    Find a price of Pentostatin bulk offered by Pfizer Inc

    Find a price of Phenytoin Sodium bulk offered by Pfizer Inc

    Find a price of Polyethylene Glycol Monostearate bulk offered by Pfizer Inc

    Find a price of Prednisolone bulk offered by Pfizer Inc

    Find a price of Prednisolone Sodium Phosphate bulk offered by Pfizer Inc

    Find a price of Prednisone bulk offered by Pfizer Inc

    Find a price of Prednisone Acetate bulk offered by Pfizer Inc

    Find a price of Reserpine bulk offered by Pfizer Inc

    Find a price of Rifabutin bulk offered by Pfizer Inc

    Find a price of Silicon Dioxide API bulk offered by Pfizer Inc

    Find a price of Spectinomycin HCl bulk offered by Pfizer Inc

    Find a price of Streptomycin bulk offered by Pfizer Inc

    Find a price of Tazobactam Sodium bulk offered by Pfizer Inc

    Find a price of Testolactone bulk offered by Pfizer Inc

    Find a price of Testosterone Enanthate bulk offered by Pfizer Inc

    Find a price of Tetracycline bulk offered by Pfizer Inc

    Find a price of Tetracycline Hydrochloride bulk offered by Pfizer Inc

    Find a price of Tinidazole bulk offered by Pfizer Inc

    Find a price of Tirilazad bulk offered by Pfizer Inc

    Find a price of Tolbutamide bulk offered by Pfizer Inc

    Find a price of Tranexamic Acid bulk offered by Pfizer Inc

    Find a price of Treprostinil Sodium bulk offered by Pfizer Inc

    Find a price of Triazolam bulk offered by Pfizer Inc

    Find a price of Troleandomycin bulk offered by Pfizer Inc

    Find a price of Vancomycin Hydrochloride bulk offered by Pfizer Inc

    Find a price of Vidarabine bulk offered by Pfizer Inc

    Find a price of Viomycin Sulfate bulk offered by Pfizer Inc

    Find a price of Zinc Gluconate API bulk offered by Pfizer Inc

    Find a price of VIRAL AND BACTERIAL VACCINE bulk offered by Pfizer Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MILAN, ITALY. bulk offered by Pfizer Inc

    Find a price of VIRAL AND BACTERIAL VACCINES bulk offered by Pfizer Inc

    Find a price of MANUFACTURING FACILITIES IN COLUMBUS, OHIO bulk offered by Pfizer Inc

    Find a price of CLINICAL INVESTIGATION--CI-383 bulk offered by Pfizer Inc

    Find a price of PERSONNEL FACILITIES AND OPERATING PROCEDURE bulk offered by Pfizer Inc

    Find a price of FACILITIES & GENERAL OPERATING PROCEDURES (SANDY, UTAH LOCATION) bulk offered by Pfizer Inc

    Find a price of PELLETHANE MDI BASED URETHANE ELASTOMER bulk offered by Pfizer Inc

    Find a price of CLINICAL INVESTIGATIONS--CI 400 AND 421 bulk offered by Pfizer Inc

    Find a price of AT THE CHRISTIANSTED, ST. CROIX LOCATION bulk offered by Pfizer Inc

    Find a price of ARA-CYTIDINE 5 - BENZOATE (U - 32,072E) bulk offered by Pfizer Inc

    Find a price of CLINICAL INVESTIGATION--CI-446 bulk offered by Pfizer Inc

    Find a price of MANFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN JOHANNESHOV, SWEDEN. bulk offered by Pfizer Inc

    Find a price of (U-31, 583) 1-B-D-ARABINOFURANOSYLCYTOSINE 5'-PALMITATE bulk offered by Pfizer Inc

    Find a price of NSC-51173, (U-10955)--5A-ANDROSTAN-3-ONE,2A-FLUORO-17B-HYDROXY bulk offered by Pfizer Inc

    Find a price of MANUFACTURING ,PACKAGING AND CONTROLS PROCEDURES-THIS IS A VET MED DMF bulk offered by Pfizer Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES OF LARGE VOLUME PARENTERALS IN GLASS BOTTLES IN UPPSALS, SWEDEN. bulk offered by Pfizer Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN HILLEROD, DENMARK. bulk offered by Pfizer Inc

    Find a price of MANUFACTURING SITE FACILITIES OPERATING PROCEDURES AND PERSONNEL OF THE GS/API PROCESS R&D PLANT IN NERVIANO ITALY bulk offered by Pfizer Inc

    Find a price of CAPSULE PLANT OPERATION AT THE DETROIT, MICHIGAN FACILITY bulk offered by Pfizer Inc

    Find a price of METHODS, FACILITIES AND CONTROLS bulk offered by Pfizer Inc

    Find a price of 17-DESOXY OXIDO bulk offered by Pfizer Inc

    Find a price of FACILITY AND OPERATING PROCEDURES IN STOCKHOLM, SWEDEN bulk offered by Pfizer Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN BRISTOL, TENNESSEE. bulk offered by Pfizer Inc

    Find a price of POLYMYXIN METHANE SULFONATE FOR TREAT. OF DISEASE IN POULTRY (VET) bulk offered by Pfizer Inc

    Find a price of CLINICAL INVESTIGATION--CI-462 bulk offered by Pfizer Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES bulk offered by Pfizer Inc

    Find a price of CLINICAL INVESTIGATION--CI 344 bulk offered by Pfizer Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GWENT, UNITED KINGDOM. bulk offered by Pfizer Inc

    Find a price of GEN. INFO APPLICABLE TO THE FINE CHEMICAL OPERATIONS bulk offered by Pfizer Inc

    Find a price of PERSONNEL, FACILITIES & GENERAL OPERATING PROCEDURES bulk offered by Pfizer Inc

    Find a price of ANTIBIOTIC GENERAL INFORMATION bulk offered by Pfizer Inc

    Find a price of CLINICAL INVESTIGATION--CI423 bulk offered by Pfizer Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN PARSIPPANY, NEW JERSEY. bulk offered by Pfizer Inc

    Find a price of QUALITY CONTROL INFORMATION FOR NDA ANTIBIOTIC bulk offered by Pfizer Inc

    Find a price of CLINICAL INVESTIGATION 461 bulk offered by Pfizer Inc

    Find a price of U-32, 070E (25-HYDROXYCHOLECALCIFEROL) bulk offered by Pfizer Inc

    Find a price of MANUFACTURING SITE, FACILITIES, OPERATING PROCEDURES AND PERSONNEL IN UPPSALA, SWEDEN. bulk offered by Pfizer Inc

    Find a price of PERSONNEL, FACILS & GEN OPER PROCEDS AT THE LITITZ, PA FACILITY bulk offered by Pfizer Inc

    Find a price of W 3361, A LIQUID ANTACID FORMULATION ---CHITOSAN ANTACID bulk offered by Pfizer Inc

    Find a price of FACILS. & CONTROLS LOCATED IN FJARDO, PUERTO RICO FACILITY bulk offered by Pfizer Inc

    Find a price of IODODOXORUBICIN HCL FOR INJECTION bulk offered by Pfizer Inc

    Find a price of SOLKETAL(GLYCEROL 1,2 - ISOPROPYLIDENE ETHER) bulk offered by Pfizer Inc

    Find a price of BIZELESIN (U-77779) DRUG SUBSTANCE bulk offered by Pfizer Inc

    Find a price of FACILITY AND OPERATING PROCEDURES IN STRANGNAS, SWEDEN bulk offered by Pfizer Inc

    Find a price of METHODS, FACILS & CONTRLS bulk offered by Pfizer Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN UPPSALA, SWEDEN. bulk offered by Pfizer Inc

    Find a price of FACILITIES, PERSONNEL & EQUIPMENT IN SANDWICH, KENT, ENGLAND bulk offered by Pfizer Inc

    Find a price of CLINICAL INVESTIGATION-- CI-395 bulk offered by Pfizer Inc

    Find a price of BULK CHEMICALS , METHOD OF PREPARATION bulk offered by Pfizer Inc

    Find a price of CLINICAL INVESTIGATION--CI 384 bulk offered by Pfizer Inc

    Find a price of QUALIFICATIONS OF PARKE, DAVIS & CO. RESEARCH PERSONNEL bulk offered by Pfizer Inc

    Find a price of PACKAGING OPERATION bulk offered by Pfizer Inc

    Find a price of MFG, PROCESS & PACK OF INDS IN MORRIS PLAINS, NJ FACIL (710 TABOR RD) bulk offered by Pfizer Inc

    Find a price of COMBINED ADRENAL HORMONE ANTIBIOTIC THERAPY bulk offered by Pfizer Inc

    Find a price of CLINICAL INVESTIGATION --CI 442 bulk offered by Pfizer Inc

    Find a price of HYDROXY ACID bulk offered by Pfizer Inc

    Find a price of CI -404 - ACTINOBOLIN SULFATE bulk offered by Pfizer Inc

    Find a price of FACILITIES AND CONTROLS IN WEST SUSSEX, U.K. bulk offered by Pfizer Inc

    Find a price of OLEANSOMYCIN AND COCCIDIOSTATS IN POULTRY FEED bulk offered by Pfizer Inc

    Find a price of 16-METHYLDIOLONE ACETATE AND S.D. VII) 9(11)-ANHYDRO-16a METHYLPREDNIS bulk offered by Pfizer Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN ARNPRIOR, ONTARIO, CANADA. bulk offered by Pfizer Inc

    Find a price of WARNER-LAMBERT, CAPS PLANT OPER, BROCKVILLE, ONTARIO, CAN FACILITY bulk offered by Pfizer Inc

    Find a price of STYRENE - MALEIC ACID COPOLYMER-TOXIC. DATA, CLIN REPTS & PHYSI CHARAC bulk offered by Pfizer Inc

    Find a price of IODODOXORUBICIN HCL BULK DRUG SUBSTANCE bulk offered by Pfizer Inc

    Find a price of 1-DESOXYEPHEDRINE bulk offered by Pfizer Inc

    Find a price of FACILITY, PERSONNEL AND OPERATING PROCEDURES IN STOCKHOLM, SWEDEN bulk offered by Pfizer Inc

    Find a price of FACILITY AND OPERATING PROCEDURES AT THE BRUNNA FACILITY IN KUNGSANGEN, SWEDEN bulk offered by Pfizer Inc

    Find a price of Hydrocortisone Acetate bulk offered by Pfizer Inc

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search